A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

Published:2013-08-25 Issue:4 Volume:72 Page:861-868
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Papadopoulos Kyriakos P.,Burris Howard A.,Gordon Michael,Lee Peter,Sausville Edward A.,Rosen Peter J.,Patnaik Amita,Cutler Richard E.,Wang Zhengping,Lee Susan,Jones Suzanne F.,Infante Jeffery R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-013-2267-x/fulltext.html

Reference25 articles.

1. Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC et al (2005) Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 65:7896–7901

2. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME et al (2004) Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10:3954–3964

3. Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12:2955–2960

4. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917

5. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma;Biochemical Pharmacology;2024-01

2. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation;Journal of Pharmaceutical Sciences;2023-09

3. Cytotoxic Cancer Drugs;Handbook of Cancer and Immunology;2022-12-25

4. Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors;Journal of Controlled Release;2022-12

5. Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor;Drug Design, Development and Therapy;2022-09